ResearcherHokkaido UniversityActive in the last 2 years
Hui Jiang
Matched on ORCID iD 0000-0003-2604-3386; OpenAlex author ID A5101822814. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 3
- Genotype-Informed Whole-Animal Kinome Screening Reveals Shared Kinase Vulnerabilities Across Driver Contexts in PDAC. Co-author DOI 10.1111/cas.70522↗
- Inhibition of NAD-GPx4 axis and MEK triggers ferroptosis to suppress pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ymthe.2025.05.037↗
- Identifying simultaneous inhibition of riboflavin metabolism and MEK as a novel therapeutic strategy for pancreatic cancer Co-author DOI 10.1101/2024.10.23.619807↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Takako Ooshio · 3 shared papers, 2024–2026 · strength 0.68
- Paper Genotype-Informed Whole-Animal Kinome Screening Reveals Shared Kinase Vulnerabilities Across Driver Contexts in PDAC. DOI 10.1111/cas.70522↗
- Paper Inhibition of NAD-GPx4 axis and MEK triggers ferroptosis to suppress pancreatic ductal adenocarcinoma. DOI 10.1016/j.ymthe.2025.05.037↗
- Paper Identifying simultaneous inhibition of riboflavin metabolism and MEK as a novel therapeutic strategy for pancreatic can… DOI 10.1101/2024.10.23.619807↗
- Masahiro Sonoshita · 3 shared papers, 2024–2026 · strength 0.68
- Paper Genotype-Informed Whole-Animal Kinome Screening Reveals Shared Kinase Vulnerabilities Across Driver Contexts in PDAC. DOI 10.1111/cas.70522↗
- Paper Inhibition of NAD-GPx4 axis and MEK triggers ferroptosis to suppress pancreatic ductal adenocarcinoma. DOI 10.1016/j.ymthe.2025.05.037↗
- Paper Identifying simultaneous inhibition of riboflavin metabolism and MEK as a novel therapeutic strategy for pancreatic can… DOI 10.1101/2024.10.23.619807↗
- Han Hai · 2 shared papers, 2025–2026 · strength 0.50
- Ryodai Yamamura · 2 shared papers, 2025–2026 · strength 0.50
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.